Mantle Cell Lymphoma Video Roundtable

Mantle cell lymphoma (MCL) is a rare, often aggressive form of non-Hodgkin lymphoma that develops when the body makes abnormal B-cells, and it is typically diagnosed at a later stage of disease. In this video series, Dr. Andre Goy sits down with Drs. Matthew Matasar and Peter Martin to discuss diagnosis, treatment, and unmet needs in MCL.

Video 1: Diagnosis of Mantle Cell Lymphoma

MCL is often diagnosed as a late-stage disease after it has spread to the gastrointestinal tract and bone marrow. The first video in this series reviews tools that are available to diagnose MCL, how physicians can accurately confirm a patient’s diagnosis, and the challenges that exist in differentiating between MCL and other diseases including chronic lymphocytic leukemia (CLL).

Up Next

Video 1: Diagnosis of Mantle Cell Lymphoma
Video 2: Treatment of Mantle Cell Lymphoma
Video 3: Analyzing the Unmet Needs in Mantle Cell Lymphoma
Video 4: Outlook on Mantle Cell Lymphoma

About the Panel

Andre Goy, MD, MS

  • Chairman and Executive Director
  • John Theurer Cancer Center
  • Hackensack University Medical Center
  • Hackensack, NJ

Matthew Matasar, MD

  • Chief of the Medical Oncology Service
  • Memorial Sloan Kettering Cancer Center Bergen
  • Montvale, NJ

Peter Martin, MD

  • Associate Professor of Medicine
  • and Chief of the Lymphoma Program
  • Weill Cornell Medicine
  • New York, NY

This video roundtable was produced by the Custom Programs division. The faculty received modest honoraria from Custom Programs for participating in this roundtable.

The faculty was solely responsible for the content presented.


Dr. Goy is on the speaker’s bureau and reports grant/research support from Acerta, Genentech, Kite/Gilead, Janssen, Pharmacyclics, and Takeda, and stocks/shares with COTA.

Dr. Matasar reports stock and other ownership interests with Merck; receiving honoraria from Bayer, Genentech, GlaxoSmithKline, Janssen, Pharmacyclics, Roche, and Seattle Genetics; consulting or advisory roles with Bayer, Genentech, Daiichi Sankyo, Juno Therapeutics, Merck, Roche, Rocket Medical, Seattle Genetics, and Teva; and research funding from Bayer, Genentech, GlaxoSmithKline, Janssen, Pharmacyclics, Roche, Rocket Medical, and Seattle Genetics.

Dr. Martin reports consulting for AstraZeneca, Bayer, Celgene, and Janssen.